Unit of Molecular Cell Biology and Transgenic Research

Dr. med Christian Beck

II. Medizinische Klinik der CAU Kiel, Dept. of Hematology and Oncology
Director: Prof. Dr. Dr. M. Kneba

 Tel. : 0431/880-2513 Fax : 0431/880-2238 Mail : c.beck@med2.uni-kiel.de

Eduard Buchner Haus, Otto Hahn Platz 9, D24118/Kiel

Dr. Christian Beck

 

Circulum Vitae
1985-1988 Study of Human Medicine University of Gießen
1989-1992 Study of Human Medicine University of Göttingen
1989-1991 Doctoral thesis , Institute of Hygene, University of Göttingen, / Prof Dr. med. W. Büttner
1991 Dept. Of Surgery University of Cincinnati, Ohio, USA
1992-1996
 Resident Dept. Hematology and Oncology Humboldt University / FU Berlin, / Prof. B.Doerken
1992-1996
 Collaboration with Research group "gene-therapy" / Prof. T. Blankenstein; Max-Delbrueck-Centre for Molecular Medicine (MDC), Berlin
1996-1998
 Resident Dept. Hematology and Oncology, University of Ulm, / Prof. F. Herrmann, Prof. L. Bergmann
1998-2000 Research associate, Dept. of Pathology, Immunology Division, Lab. Prof. H. Schreiber, University of Chicago, USA, supported by Deutsche Krebshilfe Stiftung e.V.
Since 9/2000 Resident Dept. Internal Medicine II / Hematology and Oncology , University of Kiel, / Prof. Dr. Dr. M. Kneba
2002 Board certification "Internal Medicine"
Since 1/2002 Group leader; Collaboration with Unit of Molecular Cell Biology and Transgenic Research / Prof. P. Saftig

 

Selected Publications
Beck C., Schreiber K , Schreiber H, Rowley DA (2003): "c-kit+ FcR+ myelocytes are increased in cancer and prevent the proliferation of fully cytolytic T cells in the presence of immune serum." Eur J Immunol, 33:19-28
Beck C, Bock N, Proksch E, Kneba M, Schröder O (2003): "Aphonia as a rare prodromal symptom in a case of Churg-Strauss-Syndrome (CSS) in coincidence with coeliac disease". Rheumatology 42:1565-6
Chen J., Rowley D.A., Clark T., Lee S., Zhou G., Beck C., Rowley J.D., Wang S.M. "The pattern of gene expression in mouse Gr-1(+) myeloid progenitor cells." Genomics. 2001 Oct;77(3):149-62.
Beck C., Schreiber H., Rowley D. (2001). "The role of TGF-ß in the immune-evasion of cancer". Microscopy Research & Technique , 52:387-395
Cayeux S., Richter G., Becker C., Beck C., Aicher A., Pezzutto A., Dörken B., Blankenstein T.(1997). "Lack of correlation between rejection of tumor cells co-expressing interleukin-2 and B7.1 and vaccine efficiency." Eur J Immunol 27(7): 1657-62.
Cayeux S., Qin Z., Beck C., Lange C., Blankenstein T. (1996): "Gene modified tumor cell vaccines for cancer therapy". Futura 11 :25-32
Cayeux S., Beck C., Dörken, Blankenstein T.(1996). "Coexpression of interleukin-4 and B7.1 in murine tumor cells leads to improved tumor rejection and vaccine effect compared to single gene transfectants and a classical adjuvant." Hum Gene Ther 7(4): 525-9.
Mapara M. Y., Bommert K. , Bargou R.C., Leng C., Beck C., Ludwig W.D., Gierschick P., Dörken B.(1995). "G protein subunit G alpha 16 expression is restricted to progenitor B cells during human B-cell differentiation." Blood 85(7): 1836-42.
Beck C., Cayeux S., Dörken B., Blankenstein T.(1995). "The thymidine kinase/ganciclovir-mediated "suicide" effect is variable in different tumor cells." Hum Gene Ther 6(12): 1525-30.
Cayeux S., Beck C., Aicher A., Dörken B., Blankenstein T. (1995). "Tumor cells cotransfected with interleukin-7 and B7.1 genes induce CD25 and CD28 on tumor-infiltrating T lymphocytes and are strong vaccines." Eur J Immunol 25(8): 2325-31.
Mapara M. Y., Bargou R. C., Beck C., Heilig B., Dörken B., Moldenhauer G.(1994). "Lymphotoxin-alpha/beta heterodimer is expressed on leukemic hairy cells and activated human B lymphocytes." Int J Cancer 58(2): 248-53.
Beck C., Schreiber K., Schreiber H. and Rowley D.A. (2002): "c-kit+ FcR+ myelocytes are increased in cancer and prevent the proliferation of fully cytolytic T cells in the presence of immune serum." submitted
Beck C., Bock N., Proksch E., Kneba M., Schröder O. (2002): "Aphonia as early and rare prodromal symptom in a case of Churg-Strauss-Syndrome (CSS) in coincidence with coeliac disease". submitted

 

Research

Treatment of Leukemia, especially of the chronic myeloid leukemia,
with allogeneic bone marrow transplantation is an established
procedure, bearing the risk of severe graft versus host disease as an concominant immune-phenomenon. The aim of our current project is to develop a strategy in order to selectively eliminate allloreactive T-cells but retaining those reactive against leukemia.
Members of the group: Dipl. Biochem. A. Pachnio, S. Gehrmann

This project is funded by the Deutsche José Carreras Leukämie-Stiftung e.V.